D
David A. Kaufman
Researcher at New York University
Publications - 33
Citations - 1066
David A. Kaufman is an academic researcher from New York University. The author has contributed to research in topics: ARDS & Prospective cohort study. The author has an hindex of 8, co-authored 33 publications receiving 729 citations. Previous affiliations of David A. Kaufman include Bridgeport Hospital.
Papers
More filters
Journal ArticleDOI
Early identification of patients at risk of acute lung injury: Evaluation of lung injury prediction score in a multicenter cohort study
Ognjen Gajic,Ousama Dabbagh,Pauline K. Park,Adebola O. Adesanya,Steven Y. Chang,Peter C. Hou,Harry L. Anderson,J. Jason Hoth,Mark E. Mikkelsen,Nina T. Gentile,Michelle N. Gong,Daniel Talmor,Ednan K. Bajwa,Timothy R. Watkins,Emir Festic,Murat Yilmaz,Remzi Iscimen,David A. Kaufman,Annette M. Esper,Ruxana T. Sadikot,Ivor S. Douglas,Jonathan E. Sevransky,Michael Malinchoc +22 more
TL;DR: Using routinely available clinical data, LIPS identifies patients at high risk for ALI early in the course of their illness and will alert clinicians about the risk of ALI and facilitate testing and implementation of ALi prevention strategies.
Journal ArticleDOI
Fluid Response Evaluation in Sepsis Hypotension and Shock: A Randomized Clinical Trial
Ivor S. Douglas,Philip Alapat,Keith Corl,Matthew C. Exline,Lui G. Forni,Andre Holder,David A. Kaufman,David A. Kaufman,Akram Khan,Mitchell M. Levy,Gregory S. Martin,Jennifer Sahatjian,Eric J. Seeley,Wesley H. Self,Jeremy A. Weingarten,Mark Richard James Williams,Douglas Hansell,Douglas Hansell +17 more
TL;DR: Physiologically informed fluid and vasopressor resuscitation using passive leg raise-induced stroke volume change to guide management of septic shock is safe and demonstrated lower net fluid balance and reductions in the risk of renal and respiratory failure.
Journal ArticleDOI
COVID-19 and Respiratory System Disorders: Current Knowledge, Future Clinical and Translational Research Questions.
Shari B. Brosnahan,Annemijn H. Jonkman,Annemijn H. Jonkman,Matthias C. Kugler,John S. Munger,David A. Kaufman +5 more
TL;DR: What is known about the effects of severe acute respiratory syndrome coronavirus-2 infection on different parts of the respiratory system, clues to understanding the underlying biology of respiratory disease, and current and future translation and clinical research questions are reviewed.
Journal ArticleDOI
Outcomes of Critically Ill Patients Who Received Cardiopulmonary Resuscitation
Jianmin Tian,David A. Kaufman,Stuart Zarich,Paul S. Chan,Philip Ong,Yaw Amoateng-Adjepong,Constantine A. Manthous +6 more
TL;DR: Patients requiring pressors and who experienced a CPA in an ICU were half as likely to survive to discharge and to be discharged home than patients not taking pressors, and may assist clinicians to inform consent for this procedure.
Journal ArticleDOI
TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
Jessica Sook Yuin Ho,Bobo Wing-Yee Mok,Laura Campisi,Tristan X. Jordan,Soner Yildiz,Sreeja Parameswaran,Joseph A. Wayman,Joseph A. Wayman,Natasha N. Gaudreault,David A. Meekins,Sabarish V. Indran,Igor Morozov,Jessie D. Trujillo,Yesai Fstkchyan,Raveen Rathnasinghe,Zeyu Zhu,Simin Zheng,Nan Zhao,Kris M. White,Helen Ray-Jones,Valeriya Malysheva,Michiel J. Thiecke,Siu Ying Lau,Honglian Liu,Anna Junxia Zhang,Andrew Chak-Yiu Lee,Wen-Chun Liu,Sonia Jangra,Alba Escalera,Teresa Aydillo,Betsaida Salom Melo,Ernesto Guccione,Robert Sebra,Elaine Shum,Jan Bakker,Jan Bakker,Jan Bakker,David A. Kaufman,Andre L. Moreira,Mariano Carossino,Udeni B. R. Balasuriya,Minji Byun,Randy A. Albrecht,Michael Schotsaert,Adolfo García-Sastre,Sumit K. Chanda,Emily R. Miraldi,Emily R. Miraldi,Anand D. Jeyasekharan,Benjamin R. tenOever,Mikhail Spivakov,Matthew T. Weirauch,Matthew T. Weirauch,Sven Heinz,Honglin Chen,Christopher Benner,Juergen A. Richt,Ivan Marazzi +57 more
TL;DR: In this paper, using multidimensional epigenetic, transcriptional, in-vitro, and invivo analyses, the authors reported that topoisomerase 1 (TOP1) inhibition suppresses lethal inflammation induced by SARS-CoV-2.